These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24884749)

  • 21. Antibacterial resistance: is there a way out of the woods?
    Marra A
    Future Microbiol; 2011 Jul; 6(7):707-9. PubMed ID: 21797683
    [No Abstract]   [Full Text] [Related]  

  • 22. Policy: An intergovernmental panel on antimicrobial resistance.
    Woolhouse M; Farrar J
    Nature; 2014 May; 509(7502):555-7. PubMed ID: 24877180
    [No Abstract]   [Full Text] [Related]  

  • 23. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [From the discovery of antibiotics to emerging highly drug-resistant bacteria].
    Meunier O
    Soins; 2015; (797):14-20. PubMed ID: 26154354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic resistance: An infectious arms race.
    Hede K
    Nature; 2014 May; 509(7498):S2-3. PubMed ID: 24784426
    [No Abstract]   [Full Text] [Related]  

  • 27. Do health plans have a role in limiting antibiotic resistance?
    Burns J
    Manag Care; 2014 Apr; 23(4):26-30, 32-3. PubMed ID: 24864530
    [No Abstract]   [Full Text] [Related]  

  • 28. Implementation of a Market Entry Reward within the United States.
    Daniel GW; Schneider M; Lopez MH; McClellan MB
    J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 30. Cutting the cost of drug development?
    Rawlins MD
    Nat Rev Drug Discov; 2004 Apr; 3(4):360-4. PubMed ID: 15060531
    [No Abstract]   [Full Text] [Related]  

  • 31. Why should governments invest in antibiotic drug discovery against multi-drug-resistant bacteria?
    Meletis G
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):150. PubMed ID: 25851116
    [No Abstract]   [Full Text] [Related]  

  • 32. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In the midst of the antimicrobial discovery conundrum: an overview.
    Tomaras AP; Dunman PM
    Curr Opin Microbiol; 2015 Oct; 27():103-7. PubMed ID: 26356257
    [No Abstract]   [Full Text] [Related]  

  • 34. [The course of the drug, clinical research and commercialization. Constraints, obstacles, delays and costs].
    Giri I; Rouillon F
    Encephale; 2006 Oct; 32(5 Pt 3):S858-60. PubMed ID: 17119487
    [No Abstract]   [Full Text] [Related]  

  • 35. Productivity shortfalls in drug discovery: contributions from the preclinical sciences?
    Williams M
    J Pharmacol Exp Ther; 2011 Jan; 336(1):3-8. PubMed ID: 20739456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 37. Antimicrobial resistance: what's needed.
    Tillotson G
    Lancet Infect Dis; 2015 Jul; 15(7):758-60. PubMed ID: 26122435
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of new antibacterials: a laudable aim, but what is the value?
    Tillotson GS
    Clin Infect Dis; 2010 Sep; 51(6):752-3; author reply 754-5. PubMed ID: 20731567
    [No Abstract]   [Full Text] [Related]  

  • 39. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Will the innovative medicines initiative really deliver innovative medicines?
    Wilkinson E
    Mol Oncol; 2008 Oct; 2(3):203-5. PubMed ID: 19383340
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.